NewYork-Presbyterian. The University Hospital of Columbia and Cornell.

Find A Physician

Return to NewYork-Presbyterian/Weill Cornell Physicians are the First to Test Gene Therapy as a Potential Treatment for Parkinson's Disease Overview

Hospital News

Return to NewYork-Presbyterian/Weill Cornell Physicians are the First to Test Gene Therapy as a Potential Treatment for Parkinson's Disease Overview

Research and Clinical Trials

Return to NewYork-Presbyterian/Weill Cornell Physicians are the First to Test Gene Therapy as a Potential Treatment for Parkinson's Disease Overview

Health Library

Return to NewYork-Presbyterian/Weill Cornell Physicians are the First to Test Gene Therapy as a Potential Treatment for Parkinson's Disease Overview

Clinical Services

Return to NewYork-Presbyterian/Weill Cornell Physicians are the First to Test Gene Therapy as a Potential Treatment for Parkinson's Disease Overview

NewYork-Presbyterian/Weill Cornell Physicians are the First to Test Gene Therapy as a Potential Treatment for Parkinson's Disease

NEW YORK (Nov 8, 2006)

Nathan Klein is the first person in the world to receive gene therapy in the brain to reduce the devastating effects of this disease. This research represents a significant step towards refining effective gene therapies to treat not only Parkinson's, but other neurological disorders – and could someday offer new hope to others with this debilitating disease. With over 700 ongoing clinical trials, NewYork-Presbyterian Hospital and the medical colleges of Weill Cornell and Columbia University collaborate to find answers that enhance and save lives. NewYork-Presbyterian is one of only five hospitals in the country ranked in all 16 specialties reviewed by U.S.News & World Report. To learn more, call 877-NYP-WELL, or visit nyp.org. Don't you deserve this level of care?

• Genes isolated by Columbia researchers may explain 74% of age-relaged macular degeneration cases.
• New incision-free technique for colorectal cancer surgery pioneered by NewYork-Presbyterian/Weill Cornell surgeons.
• NewYork-Presbyterian/Columbia physician develops potential nonsurgical alternative to mitral valve repair.
• NewYork-Presbyterian/Columbia physician leads clinical trial to maximize effects of biventricular pacemakers and optimize cardiac output in patients with acute heart failure.
• Weill Cornell scientists first to utilize technique to prevent genetic eye cancer in newborns.
• Columbia researchers discover that a cancer-causing protein stimulates regeneration in nerve cells damaged by neurological disease or spinal cord injury.
• Physicians at NewYork-Presbyterian/Weill Cornell improve removal of stroke-inducing blood clots from brain with use of corkscrew-like device.
• NewYork-Presbyterian/Columbia physicians lead landmark trial demonstrating carotid stenting safe for patients with asymptomatic carotid artery disease.
• Researchers at NewYork-Presbyterian/Weill Cornell discover that use of IVIg antibodies improves long-term cognitive ability of Alzheimer's patients.
• Morgan Stanley Children's Hospital physician/scientist leads international study to find less toxic treatment for children with cancer.
• NewYork-Presbyterian/Weill Cornell physician/scientists lead study concluding that current triple-drug regimens effectively treat large majority of HIV patients.
• Physicians at NewYork-Presbyterian/Columbia lead study to confirm that noninvasive gene expression testing from routine blood work can detect heart transplant rejection.
• NewYork-Presbyterian/Weill Cornell first in U.S. to offer promising chemotherapy cocktail to achieve long-term survival for some bone marrow cancer patients.
• Protein in nerve cells discovered to be "on/off switch" for chronic pain by Columbia researchers.
• NewYork-Presbyterian/Weill Cornell surgeons among first to implant new stents designed for use in delicate brain vessels.